Onco Wiki / Disease

Gastroenteropancreatic neuroendocrine tumor — GI origin (carcinoid), well-differentiated G1/G2

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDDIS-GI-NET
TypeDisease
Aliases
Appendiceal NETCarcinoid tumor (midgut)GEP-NET (non-pancreatic)GI neuroendocrine tumor (carcinoid)GI-NETIleal carcinoidRectal NETSmall bowel NETГастроентеропанкреатична нейроендокринна пухлина — ШКТ походження (карциноїд), добре-диференційована G1/G2
Statusreviewed 2026-05-03 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-NCCN-NET-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8240/3
icd_o_3_topography["C17", "C18", "C19", "C20", "C18.1"]
icd_10C17.9
who_classificationWHO Classification of Digestive System Tumours 5th ed (2019): Well-differentiated neuroendocrine tumour of small intestine/appendix/colon/rectum G1/G2

Capabilities

Notes

GI-NET (non-pancreatic) is the most common NET overall. Midgut/ileal carcinoids are prototypical: indolent growth, somatostatin receptor expression (SSTR2+), liver/mesenteric metastases, carcinoid syndrome (serotonin-driven flushing + diarrhea). Grading per WHO 2019: G1 Ki67 <3%, G2 Ki67 3–20%. Carcinoid syndrome occurs when serotonin (and other mediators) bypass hepatic metabolism — typically with liver metastases or retroperitoneal disease. SSA (octreotide/lanreotide) are the foundation of treatment: (1) symptom control and (2) antiproliferative (CLARINET, PROMID). PRRT (¹⁷⁷Lu-DOTATATE; NETTER-1 trial, Strosberg NEJM 2017) is approved for SSTR2+ midgut NETs after SSA progression — pending KB SSTR biomarker scaffolding (deferred). Key trials: CLARINET (lanreotide, Caplin NEJM 2014), PROMID (octreotide LAR, Rinke JCO 2009), NETTER-1 (PRRT, Strosberg NEJM 2017).

Used By

Algorithms

Disease

Indication

Questionnaires

Red flag

Sources